Obesity and insulin resistance: Management in diabetes;Obezite ve i̇nsulin direnci: Diyabet tedavisi

Turkish Journal of Endocrinology and Metabolism

Volumn 17, Issue 3, 2013, Pages 57-62

  Ashraff, Suhel ^a   Siddiqui, Muhammad A ^a   Carline, Thomas E ^a  

^a QUEEN MARGARET UNIVERSITY   (United Kingdom)

Author keywords

Diabetes; Insulin resistance; Management; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; COLESTILAN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FENFLURAMINE; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; MEGLITINIDE; MELANOCORTIN 4 RECEPTOR AGONIST; MELANOCORTIN RECEPTOR AGONIST; METFORMIN; NEUROPEPTIDE Y RECEPTOR AGONIST; PIOGLITAZONE; PROINSULIN; RECOMBINANT LEPTIN; ROSIGLITAZONE; SIBUTRAMINE; SITAGLIPTIN; SOMATOMEDIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; APPETITE; BODY WEIGHT; CALORIC INTAKE; COMORBIDITY; DIET RESTRICTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; FAT MALABSORPTION; FAT MASS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MALABSORPTION; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT EDUCATION; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; REVIEW; WEIGHT REDUCTION;

EID: 84883762930     PISSN: 13012193     EISSN: 13089846     Source Type: Journal    
DOI: 10.4274/Tjem.2156     Document Type: Review

References (77)

1. Bray GA, Bouchard C, James WPT. Handbook of obesity. In: Dekker M, ed. New York; 1998.
2. Kopelman P. Health risks associated with overweight and obesity. Obes Rev 2007; 8(Suppl 1):13-7
3. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis 1972;25:329-43.
4. National Institutes of Health. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Archives of Internal Medicine 1998;158:1855-67.
5. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA 1999;282:1530-8.
6. Jung RT. Obesity as a disease. Br Med Bull 1997;53:307-21.
7. World Health Organization. WHO Global Infobase: data on overweight and obesity, mean BMI, healthy diets and physical inactivity 2012. http://www.who.int/mediacentre/factsheets/fs311/en/ [Accessed 10.09.2012]
8. Wilding J. Science, medicine, and the future. Obesity treatment.BMJ 1997;315:997-1000.
9. Krentz AJ. Insulin resistance. BMJ 1996;313:1385-9.
10. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
11. Bell PM. Clinical significance of insulin resistance. Diabetic Med 1996;13:504-9.
12. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989;320: 702-6.
13. O'Rahilly S. Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997;314:955-9.
14. Saad MF, Knowler WC, Pettitt DJ, et al. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1989;1:1356-9.
15. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-70.
16. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
17. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-3.
18. Hamilton BS, Paglia D, Kwan AY, Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1995:1:953-6.
19. Halaas JL, Gajiwala KS, Maffei M, et al: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-6.
20. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996;45:988-91.
21. Burks DJ, Font de Mora J, Schubert M, et al. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 2000;407:377-82.
22. Hausberg M, Morgan DA, Mitchell JL, et al. Leptin potentiates thermogenic sympathetic responses to hypothermia: a receptor-mediated effect. Diabetes 2002:51:2434-40.
23. Godsland IF, Stevenson JC. Insulin resistance: syndrome or tendency? Lancet 1995;346:100-3.
24. Vague J. La différenciation sexuelle, facteur déterminant des formes de l'obésité. Presse Med 1947;30:339.
25. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995;96:88-98.
26. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997;46:1579-85.
27. Terry RB, Stefanick ML, Haskell WL, Wood PD. Contributions of regional adipose tissue depots to plasma lipoprotein concentrations in overweight men and women: possible protective effects of thigh fat. Metabolism 1991;40:733-40.
28. Pouliot MC, Després JP, Nadeau A, et al. Associations between regional body fat distribution, fasting plasma free fatty acid levels and glucose tolerance in premenopausal women. Int J Obes 1990:14:293-302.
29. Bergstrom RW, Newell-Morris LL, Leonetti DL, et al. Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men. Diabetes 1990;39:104-11.
30. Cnop M, Landchild MJ, Vidal J, et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 2002;51:1005-15.
31. Ross R, Freeman J, Hudson R, Janssen I. Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab 2002;87:5044-51.
32. Farin HM, Abbasi F, Reaven GM. Body mass index and waist circumference both contribute to differences in insulin-mediated glucose disposal in nondiabetic adults. Am J Clin Nutr 2006;83:47-51.
33. Kim SH, Abbasi F, Reaven GM. Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care 2004;27:1998-2002.
34. Nawaz H, Katz DL. American College of Preventive Medicine Practice Policy statement. Weight management counseling of overweight adults. Am J Prev Med 2001;21:73-8.
35. Atkins RC. Dr Atkins' new diet revolution. Avon Books, New York; 2002.
36. Astrup A, Ryan L, Grunwald GK, et al. The role of dietary fat in body fatness: evidence from a preliminary meta-analysis of ad libitum low-fat dietary intervention studies. Br J Nutr 2000;83:25-32.
37. Noël PH, Pugh JA. Management of overweight and obese adults. BMJ 2002;325:757-61.
38. Wooley SC, Garner DM. Dietary treatments for obesity are ineffective. BMJ 1994;309:655-6.
39. Garner DM, Wooley SC. Confronting the failure of behavioral and dietary treatments for obesity. Clin Psychol Rev 1991; 11:729-80.
40. Andres R, Muller DC, Sorkin JD. Long-term effects of change in body weight on all-cause mortality. A review. Ann Intern Med 1993;119:737-43.
41. Wadden AT, Stunkard AJ. Psychosocial consequences of obesity and dieting: research and clinical findings. In: Stunkard AJ, Wadden TA, eds. Obesity theory and therapy: (2st ed). New York; Raven Press; 1993;163-77.
42. Manson JE, Rimm EB, Stampfer MJ, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991;338:774-8.
43. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20: 537-44.
44. Lynch J, Helmrich SP, Lakka TA, et al. Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men. Arch Intern Med 1996;156:1307-14.
45. Spiess K, Sachs G, Pietschmann P, Prager R. A program to reduce onset distress in unselected type I diabetic patients: effects on psychological variables and metabolic control. Eur J Endocrinol 1995;132:580-6.
46. Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care 2000;23:1556-62.
47. Peyrot M, Rubin RR. Persistence of depressive symptoms in diabetic adults. Diabetes Care 1999;22:448-52.
48. Loughlan C, Mutrie N. An evaluation of the effectiveness of three interventions in promoting physical activity in a sedentary population. Health Education Journal 1997:56:154-65.
49. Brown SA. Studies of educational interventions and outcomes in diabetic adults: a meta-analysis revisited. Patient Educ Couns 1990;16:189-215.
50. Hanefeld M, Fischer S, Schmechel H, et al. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991;14:308-17.
51. Krishna S, Balas EA, Spencer DC, Griffin JZ, Boren SA. Clinical trials of interactive computerized patient education: implications for family practice. J Fam Pract 1997;45: 25-33.
52. Moore H, Summerbell CD, Greenwood DC, et al Improving management of obesity in primary care: cluster randomised trial. BMJ 2003:327:1085.
53. Edmunds L, Waters E, Elliott EJ. Evidence based paediatrics: Evidence based management of childhood obesity. BMJ 2001;323:916-9.
54. National Audit Office Tackling obesity in England. London: The Stationery Office. 2001.
55. National Institute Of Health And Clinical Excellence Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes NICE short clinical guideline 87. Developed by the Centre for Clinical Practice at NICE 2009. http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf [Accessed 10.08.2012]
56. Holman R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu 2007;13-20.
57. Yki-Järvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 1995;38:1378-88.
58. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996;19:920-6.
59. Chu JW, Abbasi F, Lamendola C, et al. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diab Vasc Dis Res 2005;2:37-41.
60. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
61. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9.
62. Dupré J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004;89:3469-73.
63. Szayna M, Doyle ME, Betkey JA, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000;141:1936-41.
64. Gallwitz B. Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vasc Health Risk Manag 2007;3:203-10.
65. Aschner P, Kipnes M, Lunceford J, et al. Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM). Diabetes Care 2006;55:A462.
66. Raz I, Hanefeld M, Xu L, et al. Sitagliptin monotherapy improved glycaemic control and beta-cell function after 18 weeks in patients with type 2 diabetes (T2DM). Diabetes 2006;55:A462.
67. Nolan JJ, Ludvik B, Beerdsden P, Joyce M, Olefsky JF. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New England Journal of Medicine 1994;331:1188-93.
68. Knowler WC, Narayan KM, Hanson RL, et al. Preventing non-insulin-dependent diabetes. Diabetes 1995;44:483-8.
69. Rachman J, Turner RC. Drugs on the horizon for treatment of type 2 diabetes. Diabet Med 1995;12:467-78.
70. Cusi K, Defronzo RA. Treatment of NIDDM, IDDM, and other insulin-resistant states with IGF-1. Diabetes Review 1995;3:206-36.
71. National Institute Of Health And Clinical Excellence The clinical effectiveness and cost effectiveness of sibutramine for obesity. 2001. http://www.nice.org.uk/guidance/TA31 [Accessed 09/07/2012]
72. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet 1998;352:167-72.
73. Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004;80:1461-8.
74. Kobayashi M, Ikegami H, Fujisawa T, et al. Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid-Binding Resin. Diabetes 2007;56:239-47.
75. Steffen KJ, Roerig JL, Mitchell JE, Uppala S. Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs 2006;11:315-36.
76. Bomberg EM, Grace MK, Levine AS, Olszewski PK. Functional interaction between nociceptin/orphanin FQ and alpha-melanocyte-stimulating hormone in the regulation of feeding. Peptides 2006;27:1827-34.
77. Galiano S, Erviti O, Pérez S, et al. Novel human neuropeptide Y Y5 receptor antagonists for the treatment of obesity. Synthesis and biological evaluation of pyridine hydrazide derivatives. Arzneimittelforschung 2005;55:81-5.